AMENDMENT TO THE CLAIMS

1-22 (Canceled)

23. (Currently Amended) A method for treating impaired respiratory function in a human patient suffering from sleep apnea~~, such as central sleep apnea or obstructive sleep apnea,~~ comprising administering to said patient an effective amount of gaboxadol per day.

24. (Currently Amended) A method for treating sleep apnea~~, such as central sleep apnea or obstructive sleep apnea,~~ in a human patient, comprising administering to said patient an effective amount of gaboxadol per day.

25. (New) The method of claim 23, wherein the sleep apnea is central sleep apnea.

26. (New) The method of claim 23, wherein the sleep apnea is obstructive sleep apnea.

27. (New) The method of claim 23, wherein the sleep apnea is a mix of central sleep apnea and obstructive sleep apnea.

28. (New) The method of claim 23, wherein the gaboxadol increases slow wave sleep in the patient and thereby improves the respiratory function.

29. (New) The method of claim 23, wherein the human patient suffers from sleep apnea and depression at the same time.

30. (New) The method of claim 23, wherein the gaboxadol is in the form of an acid addition salt, a zwitter ion hydrate, or a zwitter ion anhydrate.

31. (New) The method of claim 23, wherein the gaboxadol is in the form of its hydrochloride or hydrobromide salt.

32. (New) The method of claim 23, wherein the gaboxadol is in the form of its zwitter ion monohydrate.

33. (New) The method of claim 23, wherein the gaboxadol is administered orally.

34. (New) The method of claim 23, wherein the gaboxadol is administered in the form of an oral dosage form.

35. (New) The method of claim 34, wherein the oral dosage form is a solid dosage form.

36. (New) The method of claim 35, wherein the oral dosage form is a tablet or capsule.

37. (New) The method of claim 34, wherein the oral dosage form is a liquid dosage form.

38. (New) The method of claim 34, wherein the oral dosage form comprises from 2.5 mg to 20 mg of gaboxadol.

39. (New) The method of claim 23, wherein the human patient is selected from elderly or adults.

40. (New) The method of claim 23, wherein said treatment is intermediate term treatment.

41. (New) The method of claim 23, wherein said treatment is short term treatment.

42. (New) The method of claim 23, wherein said treatment is long term treatment.

43. (New) The method of claim 23, wherein said gaboxadol is crystalline.

44. (New) The method of claim 34, wherein the dosage form comprises an amount of from 2.5 mg to 20 mg of gaboxadol, said amount being effective during a substantial portion of a single sleep period.

45. (New) The method of claim 44, wherein the dosage form comprises 5 mg to 15 mg of gaboxadol.

46. (New) The method of claim 44, wherein said substantial portion is 50% or more.

47. (New) The method of claim 46, wherein said substantial portion is 80% or more.

48. (New) The method of claim 44, wherein said single sleep period is from one to eight hours.

49. (New) The method of claim 44, wherein the amount of gaboxadol is released from a composition for controlled release.

50. (New) The method of claim 49, wherein from 50% to 100% of the amount of gaboxadol is released within a period of three hours from administration.

51. (New) The method of claim 49, wherein from 80% to 100% of the amount of gaboxadol is released within a period of five hours from administration.